7Baggers
 Cantor Fitzgerald Boosts Earnings Estimates for Pharvaris  Defense World Mon, 17 Nov 2025 06:52:03 GMT
 Brokers Offer Predictions for Pharvaris FY2025 Earnings  Defense World Mon, 17 Nov 2025 06:51:57 GMT
 pharvaris fy2025 eps estimate boosted by leerink partnrs  Defense World Mon, 17 Nov 2025 06:51:57 GMT
 wedbush has negative estimate for pharvaris fy2029 earnings  Defense World Sun, 16 Nov 2025 13:50:49 GMT
 pharvaris (nasdaq:phvs) earns buy rating from hc wainwright  Defense World Sat, 15 Nov 2025 21:18:48 GMT
 Pharvaris price target raised to $37 from $34 at Morgan Stanley  TipRanks Fri, 14 Nov 2025 02:47:39 GMT
 Pharvaris Q3 Loss Narrows  MarketScreener Wed, 12 Nov 2025 12:09:12 GMT
 How Pharvaris N.v. (PHVS) Affects Rotational Strategy Timing  news.stocktradersdaily.com Sat, 08 Nov 2025 05:58:02 GMT
 is pharvaris n.v. stock recession proof - market risk report & fast gain swing trade alerts  Fundação Cultural do Pará Thu, 06 Nov 2025 04:08:48 GMT

Pharvaris B.V
(NASDAQ:PHVS) 

PHVS stock logo

Pharvaris is a clinical-stage company focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.

Founded: 2015
CEO: Berndt Modig  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends